{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:26:22Z","timestamp":1794119182289,"version":"4.8.0"},"reference-count":179,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.molmed.2020.09.009","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T08:16:28Z","timestamp":1602231388000},"page":"152-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies"],"prefix":"10.1016","volume":"27","author":[{"given":"Marilyn E.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-1333","authenticated-orcid":false,"given":"Gregory L.","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2020.09.009_bb0005","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/annrheumdis-2015-eular.1159","article-title":"SAT0423 understanding delay in diagnosis, access to care and satisfaction with care in lupus: findings from a cross-sectional online survey in the United States","volume":"74","author":"Al Sawah","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fimmu.2015.00457","article-title":"Female bias in systemic lupus erythematosus is associated with the differential expression of X-linked toll-like receptor 8","volume":"6","author":"McDonald","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0015","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/rheumatology\/ket160","article-title":"Effect of gender on clinical presentation in systemic lupus erythematosus","volume":"52","author":"Murphy","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2020.09.009_bb0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3389\/fimmu.2018.00611","article-title":"Gender bias in human systemic lupus erythematosus: a problem of steroid receptor action?","volume":"9","author":"Rider","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2020.09.009_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2016.07.001","article-title":"The diagnosis and management of the haematologic manifestations of lupus","volume":"74","author":"Velo-Garc\u00eda","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2020.09.009_bb0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy","volume":"16","author":"Maria","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12916-015-0269-8","article-title":"Neuropsychiatric lupus: a mosaic of clinical presentations","volume":"13","author":"Kivity","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semarthrit.2018.01.010","article-title":"Pulmonary manifestations in late versus early systemic lupus erythematosus: a systematic review and meta-analysis","volume":"48","author":"Medlin","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0050","article-title":"Pericarditis in lupus","volume":"11","author":"Dein","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.semarthrit.2011.11.002","article-title":"Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s","volume":"41","author":"Mak","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0060","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/0961203318786436","article-title":"SLE mortality remains disproportionately high, despite improvements over the last decade","volume":"27","author":"Singh","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0065","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.40512","article-title":"Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015","volume":"70","author":"Yen","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.it.2018.04.006","article-title":"Metabolism as a target for modulation in autoimmune diseases","volume":"39","author":"Huang","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.12847","article-title":"Metabolic determinants of lupus pathogenesis","volume":"295","author":"Teng","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molmed.2020.09.009_bb0080","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/17460441.2018.1480718","article-title":"Proteomic approaches for novel systemic lupus erythematosus (SLE) drug discovery","volume":"13","author":"Li","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.molmed.2020.09.009_bb0085","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41584-020-0470-9","article-title":"Clinical value of DNA methylation markers in autoimmune rheumatic diseases","volume":"16","author":"Ballestar","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2015.33","article-title":"Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis","volume":"11","author":"Mohan","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0095","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s41598-017-06516-1","article-title":"Novel risk genes for systemic lupus erythematosus predicted by random forest classification","volume":"7","author":"Alml\u00f6f","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2020.09.009_bb0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/BOR.0000000000000654","article-title":"An update on the genetics of systemic lupus erythematosus","volume":"31","author":"Oparina","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0105","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.09.009_bb0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0115","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jaci.2015.04.008","article-title":"Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus","volume":"136","author":"O\u2019Gorman","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0120","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.2130","article-title":"A CD8+ T cell transcription signature predicts prognosis in autoimmune disease","volume":"16","author":"McKinney","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0125","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2020.09.009_bb0130","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s10067-016-3404-9","article-title":"Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity","volume":"35","author":"Gupta","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0135","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0140","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93009","article-title":"Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis","volume":"2","author":"Der","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2020.09.009_bb0150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2020.09.009_bb0155","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome","volume":"18","author":"Korbet","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-018-1561-8","article-title":"Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus","volume":"20","author":"Barnado","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0165","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-015-0702-6","article-title":"Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research","volume":"17","author":"Mikdashi","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0170","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.jaut.2019.102359","article-title":"The pathogenesis of systemic lupus erythematosus: harnessing big data to understand the molecular basis of lupus","volume":"110","author":"Catalina","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2020.09.009_bb0175","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1038\/s41598-019-45989-0","article-title":"Machine learning approaches to predict lupus disease activity from gene expression data","volume":"9","author":"Kegerreis","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2020.09.009_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122312","article-title":"Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus","volume":"5","author":"Haynes","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2020.09.009_bb0185","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar2450","article-title":"The renal metallothionein expression profile is altered in human lupus nephritis","volume":"10","author":"Faurschou","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1083\/jcb.201006052","article-title":"Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps","volume":"191","author":"Papayannopoulos","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0195","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of human systemic lupus erythematosus: a cellular perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0200","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrrheum.2010.46","article-title":"The role of defective clearance of apoptotic cells in systemic autoimmunity","volume":"6","author":"Mu\u00f1oz","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2012.08.019","article-title":"Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)","volume":"12","author":"Biazar","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.molmed.2020.09.009_bb0215","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1172\/JCI105479","article-title":"Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus","volume":"45","author":"Tan","year":"1966","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2020.09.009_bb0220","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3389\/fimmu.2019.01667","article-title":"Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2015.03.007","article-title":"Clinical presentation of human C1q deficiency: how much of a lupus?","volume":"67","author":"Stegert","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0235","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1191\/096120399678847380","article-title":"Recombinant human DNAse I (rhDNASe) in patients with lupus nephritis","volume":"8","author":"Davis","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0240","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0961203316678675","article-title":"Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study","volume":"26","author":"Burge","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0245","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fimmu.2019.00538","article-title":"MMP-9\/gelatinase B degrades immune complexes in systemic lupus erythematosus","volume":"10","author":"Ugarte-Berzal","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0250","first-page":"447","article-title":"The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies","volume":"3","author":"Frost","year":"1968","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00541153","article-title":"Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus","volume":"1","author":"Chitrabamrung","year":"1981","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.molmed.2020.09.009_bb0260","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1039\/b904701h","article-title":"Multidimensional degradomics identifies systemic autoantigens and intracellular matrix proteins as novel gelatinase B\/MMP-9 substrates","volume":"1","author":"Cauwe","year":"2009","journal-title":"Integr. Biol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/mp.56.4.244","article-title":"Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus","volume":"56","author":"Makowski","year":"2003","journal-title":"Mol. Pathol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0270","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/art.1780331018","article-title":"D-penicillamine-induced lupus erythematosus","volume":"33","author":"Enzenauer","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D398Z6B5VT","article-title":"Drug-induced subacute cutaneous lupus erythematosus related to doxycycline","volume":"17","author":"Miller","year":"2011","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.molmed.2020.09.009_bb0280","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cjp2.99","article-title":"Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression","volume":"4","author":"Pedersen","year":"2018","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.molmed.2020.09.009_bb0285","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.1073\/pnas.1607011113","article-title":"Scavenging nucleic acid debris to combat autoimmunity and infectious disease","volume":"113","author":"Holl","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.09.009_bb0290","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0295","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0300","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2018-213523","article-title":"Humanised effector-null Fc\u03b3RIIA antibody inhibits immune complex-mediated proinflammatory responses","volume":"78","author":"Chen","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0305","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2010.04.027","article-title":"Dendrimer toxicity: Let\u2019s meet the challenge","volume":"394","author":"Jain","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.molmed.2020.09.009_bb0310","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1744-9987.2008.00591.x","article-title":"Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis","volume":"12","author":"Yamaji","year":"2008","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.molmed.2020.09.009_bb0315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1526-0968.2001.00302.x","article-title":"Apheresis in lupus nephritis","volume":"5","author":"Mistry-Burchardi","year":"2001","journal-title":"Ther. Apher."},{"key":"10.1016\/j.molmed.2020.09.009_bb0320","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jca.10020","article-title":"Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis","volume":"17","author":"Danieli","year":"2002","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.molmed.2020.09.009_bb0325","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0330","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.23.021704.115633","article-title":"IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors","volume":"23","author":"Liu","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/BOR.0000000000000087","article-title":"Advances in understanding the role of type I interferons in systemic lupus erythematosus","volume":"26","author":"Crow","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.molmed.2020.09.009_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0350","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/art.23268","article-title":"Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells","volume":"58","author":"Yan","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0355","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1126\/science.1064890","article-title":"Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus","volume":"294","author":"Blanco","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.molmed.2020.09.009_bb0360","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/imt-2016-0090","article-title":"Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus","volume":"9","author":"Greth","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.molmed.2020.09.009_bb0370","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0380","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0385","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0390","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0395","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0400","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1002\/eji.200737711","article-title":"CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving Syk, Slp65 and PLCgamma2","volume":"37","author":"R\u00f6ck","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050248","article-title":"BDCA2\/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells","volume":"5","author":"Cao","year":"2007","journal-title":"PLoS Biol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0410","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2020.09.009_bb0415","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/art.23186","article-title":"Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18","volume":"58","author":"Tucci","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0420","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.imbio.2009.06.013","article-title":"Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage","volume":"214","author":"Vermi","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.molmed.2020.09.009_bb0425","first-page":"148","article-title":"Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P T"},{"key":"10.1016\/j.molmed.2020.09.009_bb0430","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0435","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0440","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.27515","article-title":"Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus","volume":"62","author":"Bekar","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0445","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0450","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007429","article-title":"Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study","volume":"96","author":"Chavarot","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.molmed.2020.09.009_bb0455","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.clml.2018.05.009","article-title":"An evidence-based review of anti-CD20 antibody-containing regimens for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, or follicular lymphoma","volume":"18","author":"Falchi","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.molmed.2020.09.009_bb0460","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.molmed.2020.09.009_bb0465","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0470","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0475","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.166.5.2913","article-title":"Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide","volume":"166","author":"Daikh","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0480","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1126\/science.7520604","article-title":"Treatment of murine lupus with CTLA4Ig","volume":"265","author":"Finck","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.molmed.2020.09.009_bb0485","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/art.34624","article-title":"Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions","volume":"64","author":"Wofsy","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0490","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0495","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0500","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.37940","article-title":"Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials","volume":"65","author":"Wofsy","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0505","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.smim.2005.02.001","article-title":"Homeostatic niche specification among na\u00efve and activated B cells: a growing role for the BLyS family of receptors and ligands","volume":"17","author":"Crowley","year":"2005","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0510","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431X20154853","article-title":"Expression of BAFF and BR3 in patients with systemic lupus erythematosus","volume":"49","author":"Duan","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.molmed.2020.09.009_bb0515","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/rheumatology\/ker282","article-title":"Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study","volume":"50","author":"Eilertsen","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.molmed.2020.09.009_bb0520","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1084\/jem.20100086","article-title":"Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice","volume":"207","author":"Scapini","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0525","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.4049\/jimmunol.1101784","article-title":"BAFF\/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus","volume":"187","author":"Huang","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0530","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1084\/jem.20062567","article-title":"BAFF and MyD88 signals promote a lupuslike disease independent of T cells","volume":"204","author":"Groom","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0535","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0540","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2020.09.009_bb0545","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: first targeted biological treatment for systemic lupus erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.molmed.2020.09.009_bb0550","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.molmed.2020.09.009_bb0555","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/modpathol.2010.184","article-title":"Intrarenal production of B-cell survival factors in human lupus nephritis","volume":"24","author":"Neusser","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0560","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2020.09.009_bb0565","doi-asserted-by":"crossref","DOI":"10.1186\/ar3100","article-title":"Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus","volume":"12","author":"Dolff","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0570","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crisp\u00edn","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0575","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/096120300678828703","article-title":"Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus","volume":"9","author":"Wong","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0580","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clim.2008.01.019","article-title":"Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity","volume":"127","author":"Wong","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0585","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2008.09.019","article-title":"IL-17 producing CD4+ T cells mediate accelerated ischemia\/reperfusion-induced injury in autoimmunity-prone mice","volume":"130","author":"Edgerton","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0590","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ni1552","article-title":"Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice","volume":"9","author":"Hsu","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0595","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.4049\/jimmunol.0900385","article-title":"The role of IL-23\/IL-17 axis in lupus nephritis","volume":"183","author":"Zhang","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0600","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.4049\/jimmunol.0903595","article-title":"Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL\/6-lpr\/lpr mice","volume":"184","author":"Kyttaris","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0605","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2249.1999.00862.x","article-title":"Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines","volume":"116","author":"Tokano","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0610","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1191\/0961203302lu213oa","article-title":"Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity","volume":"11","author":"Lauwerys","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0615","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2020.09.009_bb0620","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0625","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.4049\/jimmunol.166.6.4216","article-title":"Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus","volume":"166","author":"Solomou","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0630","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.09.009_bb0635","doi-asserted-by":"crossref","first-page":"740619","DOI":"10.1155\/2010\/740619","article-title":"The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity","volume":"2010","author":"Lieberman","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0640","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0645","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2020.09.009_bb0650","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12877-017-0574-5","article-title":"Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing","volume":"17","author":"Schlender","year":"2017","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.molmed.2020.09.009_bb0655","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.4049\/jimmunol.1403088","article-title":"Metformin suppresses systemic autoimmunity in roquin san\/san mice through inhibiting B cell differentiation into plasma cells via regulation of AMPK\/mTOR\/STAT3","volume":"198","author":"Lee","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0660","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trsl.2014.10.002","article-title":"Interferon regulatory factors: critical mediators of human lupus","volume":"165","author":"Jensen","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.molmed.2020.09.009_bb0665","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0670","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0675","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2020.09.009_bb0680","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0685","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2020.09.009_bb0690","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/art.40653","article-title":"Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression","volume":"70","author":"Toro-Dom\u00ednguez","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0695","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99276","article-title":"Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus","volume":"3","author":"Carlucci","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2020.09.009_bb0700","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0705","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0710","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.09.009_bb0715","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.niox.2010.01.001","article-title":"Nitric oxide donors release extracellular traps from human neutrophils by augmenting free radical generation","volume":"22","author":"Patel","year":"2010","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.molmed.2020.09.009_bb0720","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0725","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/art.37893","article-title":"Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus","volume":"65","author":"Garcia","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0730","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1002\/art.39296","article-title":"Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin","volume":"67","author":"Wang","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0735","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2020.09.009_bb0740","first-page":"906","article-title":"Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment","volume":"37","author":"Zhang","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0745","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.biomaterials.2013.10.046","article-title":"The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus","volume":"35","author":"Look","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.molmed.2020.09.009_bb0750","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1172\/JCI65907","article-title":"Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice","volume":"123","author":"Look","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2020.09.009_bb0755","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1681\/ASN.2009030295","article-title":"siRNA-based therapy ameliorates glomerulonephritis","volume":"21","author":"Shimizu","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0760","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000176","article-title":"Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus","volume":"4","author":"Aberle","year":"2017","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0765","first-page":"1245","article-title":"The state of lupus clinical trials: minority participation needed","volume":"8","author":"Sheikh","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.molmed.2020.09.009_bb0770","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0775","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000258","article-title":"Lupus community panel proposals for optimising clinical trials: 2018","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0780","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.09.009_bb0785","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0790","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2020.09.009_bb0795","first-page":"1709","article-title":"Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period","volume":"32","author":"Clark","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0800","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.berh.2013.07.005","article-title":"Managing lupus patients during pregnancy","volume":"27","author":"Lateef","year":"2013","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0805","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaut.2016.07.010","article-title":"Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. a prospective multicenter study","volume":"74","author":"Moroni","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2020.09.009_bb0810","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.berh.2017.09.011","article-title":"Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome","volume":"31","author":"Fischer-Betz","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0815","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3899\/jrheum.171023","article-title":"Monitoring of systemic lupus erythematosus pregnancies: a systematic literature review","volume":"45","author":"McDonald","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0820","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0825","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2020.09.009_bb0830","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0835","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(01)06004-4","article-title":"Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases","volume":"358","author":"Klinger","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2020.09.009_bb0840","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203319843343","article-title":"Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia","volume":"28","author":"Seo","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0845","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2020.09.009_bb0850","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0961203310388445","article-title":"International consensus for a definition of disease flare in lupus","volume":"20","author":"Ruperto","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.molmed.2020.09.009_bb0855","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-016-0562-3","article-title":"What Causes Lupus Flares?","volume":"18","author":"Fernandez","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.molmed.2020.09.009_bb0860","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0865","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0870","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/acr.20097","article-title":"Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort","volume":"62","author":"Pons-Estel","year":"2010","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.molmed.2020.09.009_bb0875","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2020.09.009_bb0880","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0885","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3899\/jrheum.170158","article-title":"Risk of retinal toxicity in longterm users of hydroxychloroquine","volume":"44","author":"Kim","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0890","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.molmed.2020.09.009_bb0895","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420302562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420302562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:22:11Z","timestamp":1761463331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491420302562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":179,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1471491420302562"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2020.09.009","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2020.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}